The development status of epigenetic drugs. KDMi, lysine demethylase inhibitor; KMTi, lysine methyltransferase inhibitor; HATi, histone acetyltransferase inhibitor; HDACi, histone deacetylase inhibitor; BETi, bromodomain and extracarboxy terminal domain inhibitor; DNMTi, DNA methyltransferase inhibitor.